Cellectar Biosciences Inc (CLRB) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CLRB Annual Balance Sheets →
The data below summarizes Cellectar Biosciences Inc's balance sheet position from Mar 31 2025 to Mar 31 2026, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent8.35
Cash & Short-term Investments8.00
Prepaid Expense And Other Assets Current0.92
Total Current Assets9.27
Equipment/Property/Plant Net0.34
Other Assets, Noncurrent1.51
Operating Lease Right Of Use Asset1.48
Total Assets11.12
Liabilities
Accounts Payable and Accrued Liabilities, Current LI4.72
Derivative Liability, Current DE0.15
Other Liabilities, Current0.00
Total Current Liabilities4.87
Total Long-term Debt0.00
Other liabilities, Noncurrent1.53
Operating Lease Liability Current-
Operating Lease Liability Noncurrent1.53
Total Liabilities6.40
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock277.60
Retained Earnings / Accumulated Deficit-274.79
Other Equity-1.38
Common Stockholder's Equity1.43
Preferred Stockholder's Equity0.52
Non-controlling interests & other1.38
Total Stockholder's Equity3.34
Liabilities & Stockholder's Equity11.12
4 historic quarters locked

Sign in to unlock the full Cellectar Biosciences Inc balance sheet history.

About Cellectar Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-095426

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.